Maurice P H M Jansen

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer
    M P H M Jansen
    Department of Medical Oncology, Josephine Nefkens Institute and Cancer Genomics Center, Erasmus Medical Center Rotterdam, Room Be401, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Breast Cancer Res Treat 133:937-47. 2012
  2. ncbi Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
    Sherene Loi
    Functional Genomics Unit, Jules Bordet Institute, Brussels, Belgium
    BMC Genomics 9:239. 2008
  3. ncbi Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer
    Maurice P H M Jansen
    Department of Medical Oncology, Erasmus MC, Josephine Nefkens Institute, Rotterdam, The Netherlands
    Breast Cancer Res Treat 116:263-71. 2009
  4. ncbi HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study
    Maurice P H M Jansen
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 25:662-8. 2007
  5. ncbi TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer
    Danielle Meijer
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC, Room Be 432, P O Box 2040, 3000 CA, Rotterdam, The Netherlands
    Breast Cancer Res Treat 113:253-60. 2009
  6. ncbi Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response
    Jozien Helleman
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Clin Cancer Res 14:5555-64. 2008
  7. ncbi Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture
    Jozien Helleman
    Department of Medical Oncology, Erasmus MC JNI Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Gynecol Oncol 117:170-6. 2010
  8. ncbi Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling
    Maurice P H M Jansen
    Department of Medical Oncology, Erasmus MC/Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 23:732-40. 2005
  9. ncbi Molecular profiling of platinum resistant ovarian cancer
    Jozien Helleman
    Department of Medical Oncology, Erasmus MC/Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
    Int J Cancer 118:1963-71. 2006
  10. ncbi Integrated genomics of chemotherapy resistant ovarian cancer: a role for extracellular matrix, TGFbeta and regulating microRNAs
    Jozien Helleman
    Department of Medical Oncology, Erasmus MC JNI, Rotterdam, The Netherlands
    Int J Biochem Cell Biol 42:25-30. 2010

Collaborators

Detail Information

Publications12

  1. ncbi High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer
    M P H M Jansen
    Department of Medical Oncology, Josephine Nefkens Institute and Cancer Genomics Center, Erasmus Medical Center Rotterdam, Room Be401, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Breast Cancer Res Treat 133:937-47. 2012
    ..Cell cycle regulation is the only overlapping pathway linked to miR-26a and EZH2 levels. Low mRNA levels of EZH2, CCNE1, and CDC2, and high levels of miR-26a are associated with favorable outcome on tamoxifen...
  2. ncbi Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
    Sherene Loi
    Functional Genomics Unit, Jules Bordet Institute, Brussels, Belgium
    BMC Genomics 9:239. 2008
    ..Independent validation was performed using 362 tamoxifen-treated ER+ BC samples obtained from multiple institutions and treated with tamoxifen only in the adjuvant and metastatic settings...
  3. ncbi Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer
    Maurice P H M Jansen
    Department of Medical Oncology, Erasmus MC, Josephine Nefkens Institute, Rotterdam, The Netherlands
    Breast Cancer Res Treat 116:263-71. 2009
    ..The aim of this study was to evaluate SIAH2 for its (a) predictive/prognostic value, and (b) functional role in endocrine therapy resistance...
  4. ncbi HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study
    Maurice P H M Jansen
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 25:662-8. 2007
    ..However, this ratio may predict a tumor's response to tamoxifen, its intrinsic aggressiveness, or both...
  5. ncbi TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer
    Danielle Meijer
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC, Room Be 432, P O Box 2040, 3000 CA, Rotterdam, The Netherlands
    Breast Cancer Res Treat 113:253-60. 2009
    ..Both TSC22D1 and PSAP are associated with clinical outcome and may have a functional role in therapy resistance...
  6. ncbi Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response
    Jozien Helleman
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Clin Cancer Res 14:5555-64. 2008
    ....
  7. ncbi Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture
    Jozien Helleman
    Department of Medical Oncology, Erasmus MC JNI Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Gynecol Oncol 117:170-6. 2010
    ..With this exploratory study, we aim to identify overlapping pathways associated with platinum-based chemotherapy resistance mechanisms in ovarian cancer...
  8. ncbi Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling
    Maurice P H M Jansen
    Department of Medical Oncology, Erasmus MC/Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 23:732-40. 2005
    ..Additional studies are needed to confirm if the predictive signature might allow identification of individual patients who could benefit from other (adjuvant) endocrine therapies...
  9. ncbi Molecular profiling of platinum resistant ovarian cancer
    Jozien Helleman
    Department of Medical Oncology, Erasmus MC/Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
    Int J Cancer 118:1963-71. 2006
    ..A larger independent multicentre study should further confirm whether this 9-gene set can identify the patients who will not respond to platinum-based chemotherapy and could benefit from other therapies...
  10. ncbi Integrated genomics of chemotherapy resistant ovarian cancer: a role for extracellular matrix, TGFbeta and regulating microRNAs
    Jozien Helleman
    Department of Medical Oncology, Erasmus MC JNI, Rotterdam, The Netherlands
    Int J Biochem Cell Biol 42:25-30. 2010
    ..A model is presented based on literature linking transforming growth factor beta, extracellular matrix, integrin signalling, epithelial to mesenchymal transition and regulating microRNAs with a (bivalent) role in chemotherapy response...
  11. ncbi Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen
    Diana E Ramirez-Ardila
    Department of Medical Oncology, Erasmus MC Cancer Institute, Room Be424, PO Box 2040, 3000 CA, Rotterdam, The Netherlands
    Breast Cancer Res Treat 139:39-49. 2013
    ..Mutations were not associated with prognosis in untreated LNN patients nor predictive outcome after first-line tamoxifen therapy in advanced disease patients...
  12. ncbi Re: Limits of predictive models using microarray data for breast cancer clinical treatment outcome
    Maurice P H M Jansen
    J Natl Cancer Inst 97:1851-2; author reply 1852-3. 2005